Allergen-Specific Immunotherapy with Recombinant Allergens
- 15 March 2011
- book chapter
- Published by Springer Nature
- Vol. 352, 43-54
Abstract
Subcutaneous immunotherapy is a well-documented treatment of allergic rhinitis and asthma. The major limitation is the risk of anaphylactic side effects. The documentation of clinical efficacy is based on crude allergenic extracts sometimes containing varying amounts of individual allergens including allergens to which the patient may not be sensitized. The introduction of recombinant allergens offer a possibility to use well-defined molecules with consistent pharmaceutical quality defined in mass units. The proof-of-concept of the clinical efficacy of recombinant allergens is based on two studies published as full articles. One study applied a mixture of five Phleum pratense major allergens in a maximum dose of 40 μg protein. The clinical efficacy showed a significant efficacy with about 40% reduction in disease severity. The second study compared a commercial birch extract with both recombinant Bet v 1 and purified Bet v 1 in dosages of 15 μg allergen. The clinical effect was around 60% additional efficacy. Systemic side effects occurred more frequently with grass allergens. A third study used hypoallergenic fragments and a trimer of Bet v 1. The study did not show efficacy and a rather high frequency of systemic side effects. The advantages of using recombinant allergens for immunotherapy are obvious but more large-scale clinical studies are needed before the overall value in terms of efficacy and safety can be determined.Keywords
This publication has 29 references indexed in Scilit:
- Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivativesClinical & Experimental Allergy, 2008
- Review article: From allergen genes to new forms of allergy diagnosis and treatmentAllergy, 2008
- EU Forum: The CREATE Project: development of certified reference materials for allergenic products and validation of methods for their quantificationAllergy, 2008
- Allergen-specific immunotherapy with recombinant grass pollen allergensJournal of Allergy and Clinical Immunology, 2005
- Strategies for converting allergens into hypoallergenic vaccine candidatesMethods, 2004
- Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergensJournal of Allergy and Clinical Immunology, 2001
- Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild‐type by skin prick and intradermal testing: results obtained in a French populationClinical & Experimental Allergy, 2000
- Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: Results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season☆☆☆★Journal of Allergy and Clinical Immunology, 1999
- Diagnosis of Grass Pollen Allergy with Recombinant Timothy Grass (Phleum pratense) Pollen AllergensInternational Archives of Allergy and Immunology, 1992
- Recombinant allergens for immunoblot diagnosis of tree-pollen allergyJournal of Allergy and Clinical Immunology, 1991